跳至主要内容
临床试验/NCT05952141
NCT05952141招募中不适用

Thibang Diphatlha: Testing Adaptive Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana

Abramson Cancer Center at Penn Medicine3 个研究点 分布在 2 个国家目标入组 610 人开始时间: 2023年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
610
试验地点
3
主要终点
Adoption

研究概览

简要总结

Investigators will test the effectiveness of adaptive strategies on timely adoption of cervical cancer treatment in Botswana using a pragmatic trial design.

详细描述

Investigators will test the effectiveness of adaptive strategies on timely adoption of cervical cancer treatment in Botswana using a hybrid (type III) and pragmatic Sequential Multiple Assignment Randomized Trial (SMART) design. The adaptive strategies are designed to target patient- and system-level determinants identified in preliminary data, including delayed communication of results, individual and structural barriers to accessing treatment, and suboptimal care coordination between referring and cancer treatment clinics. The strategies draw upon key principles in behavioral economics and are supported by systematic evidence of the effectiveness of nudge strategies in preventive, HIV, and cancer care. The overarching rationale for the study is that enhancing coordination, communication, and navigation through centralized outreach and nudge strategies will increase timely treatment adoption and be scalable and sustainable in the long-term.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Health Services Research
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients will be eligible if they:
  • are biological females
  • are aged 18 or older
  • have pathology-confirmed invasive cervical cancer diagnosis
  • have pathology results evaluated at National Health Laboratory in Botswana
  • are citizens of Botswana
  • have no prior history of invasive cervical cancer

排除标准

  • Patients will be excluded if they:
  • are biological males or otherwise born without a cervix
  • are below the age of 18 due to the rarity of cervical cancer in this population
  • do not meet study inclusion criteria

研究组 & 干预措施

Stage 1 Clinic Outreach + Stage 2 High Touch

Experimental

All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation (stage 2).

干预措施: Clinic Outreach (Behavioral)

Stage 1 Clinic Outreach + Stage 2 Low Touch

Experimental

All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).

干预措施: Clinic Outreach (Behavioral)

Stage 1 Clinic Outreach + Stage 2 Low Touch

Experimental

All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).

干预措施: Low-Touch Strategy (Behavioral)

Stage 1 Clinic Outreach + Stage 2 High Touch

Experimental

All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation (stage 2).

干预措施: High-Touch Strategy (Behavioral)

Stage 1 Enhanced Outreach + Stage 2 Low-Touch

Experimental

All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).

干预措施: Enhanced Outreach (Behavioral)

Stage 1 Enhanced Outreach + Stage 2 Low-Touch

Experimental

All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).

干预措施: Low-Touch Strategy (Behavioral)

Stage 1 Enhanced Outreach + Stage 2 High-Touch

Experimental

All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation.

干预措施: Enhanced Outreach (Behavioral)

Stage 1 Enhanced Outreach + Stage 2 High-Touch

Experimental

All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation.

干预措施: High-Touch Strategy (Behavioral)

结局指标

主要结局

Adoption

时间窗: Within 90 days of randomization

Defined as the initiation of cervical cancer treatment within 90 days of randomization.

次要结局

  • Reach: First Stage(12 months after randomization)
  • Fidelity(12 months after randomization)
  • Reach: First Appointment(12 months after randomization)
  • Reach: Second Stage(12 months after randomization)
  • Reach: Results(12 months after randomization)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Katharine Rendle

Principal Investigator

Abramson Cancer Center at Penn Medicine

研究点 (3)

Loading locations...

相似试验